Navigation Links
Bernstein Liebhard LLP Announces That A Securities Class Action Has Been Filed Against Aveo Pharmaceutical, Inc.
Date:5/10/2013

NEW YORK, May 10, 2013 /PRNewswire/ -- Bernstein Liebhard LLP today announced that a securities class action has been commenced in the United States District Court for the District of Massachusetts on behalf of a class (the "Class") of purchasers of Aveo Pharmaceutical, Inc. ("Aveo" or the "Company") (NASDAQ: AVEO) securities between January 3, 2012 and May 1, 2013 (the "Class Period").

Aveo is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapies.  The Company's lead product is an oral inhibitor of the vascular endothelial growth factor ("VEGF") receptors.

The Complaint alleges that throughout the Class Period, Defendants conditioned investors to believe that the Company's drug Tivopath (or Tivozanib) would receive approval from the U.S. Food and Drug Administration ("FDA") through a host of materially false and misleading statements regarding its Phase III ("TIVO-1") trial design and results.  Specifically, the Company (a) failed to disclose to investors that the FDA had recommended that the Company conduct an additional Phase III trial due to adverse trends in the Company's first study; (b) misled investors regarding the overall safety and efficacy of the product, including failing to disclose the 25% higher rate of death associated with Tivozanib therapy compared to the control drug, Sorafenib; and (c) failed to disclose that almost 90% of the patients studied in TIVO-1 were enrolled from sites in Central and Eastern Europe with inconsistent treatment patterns from those in the U.S.  As a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.

On April 30, 2013, the FDA released its Oncologic Drugs Advisory Committee ("ODAC")
'/>"/>

SOURCE Bernstein Liebhard LLP
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference
2. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
3. Par Pharmaceutical Companies, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By TPG
4. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Abiomed, Inc.
5. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... October 17, 2014 Investor-Edge has ... (NASDAQ: ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ... research on these five companies can be accessed at: ... Thursday, October 16, 2014, ended on a mixed note ...
(Date:10/17/2014)... -- UBM Medica US announces that Endocrinology Network , ... who treat patients with type 2 diabetes ... insulin .  Nearly all patients with ... – daily injections of one or more insulin formulations—to ... of pancreatic beta cells. Insulin is a very effective ...
(Date:10/17/2014)...  China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... approval from the China Food and Drug Administration ... complex concentrate ("PCC") at its Shandong Taibang facility. ... production facility for Good Manufacturing Practices ("GMP") compliance ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
... Laser,Centers, the largest provider of laser hair removal ... the addition of the VelaShape,cellulite reduction and body ... 30 additional locations before the end of March, ... FDA-approved for both cellulite,reduction and circumferential reduction of ...
... has,received its third $10 million tranche of equity funding ... milestones:,validating the efficacy and safety of its two topical ... influenza vaccine in,ferret studies., The company, a spin-off ... $30 million over the past 18 months from Perseus ...
Cached Medicine Technology:American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment 2NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2
(Date:10/20/2014)... October 20, 2014 Based on ... the only imaging assays capable of determining DNA ... test.  With these three dimensions of high-resolution data, ... detect the widest range of disease-causing genetic rearrangements, ... by other genomic tools, including today’s advanced sequencing ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
(Date:10/19/2014)... 20, 2014 The leading review ... http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the best Dedicated ... for those who want to buy high quality ... , The IT manager of Top10BestSEOHosting.com says, “We ... recommended suppliers for everyone. A lot of the ...
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... and delay in return of spontaneous circulation (ROSC), evidenced ... were both associated with poor neurologic outcomes in post ... Nov. 14 at the at the American Heart Association ... have an appropriate understanding of the patient,s post cardiac ...
... , MONDAY, Nov. 14 (HealthDay News) -- ... to greatly increase the risk of Parkinson,s disease, and ... of developing the neurodegenerative disorder, a new study indicates. ... States have Parkinson,s disease and more than 50,000 new ...
... HealthDay Reporter , SUNDAY, Nov. 13 (HealthDay News) -- ... athletes dying on the playing field due to an undetected ... issued guidelines aimed at helping doctors and coaches detect these ... new research suggests that only a small percentage of physicians ...
... to research linking alcohol to breast cancer risk, a new ... shows that adolescent girls with a family history of breast ... become cancer have a higher risk of developing benign ... girls without a family history, this already-elevated risk rises with ...
... contributes to the increasing evidence that repeated occupational ... for Parkinson,s disease. Researchers analyzed the occupational histories ... developed the neurodegenerative disorder, and assessed that twin,s ... to Parkinson,s. Of the six chemicals investigated, researchers ...
... , SUNDAY, Nov. 13 (HealthDay News) -- Patients who ... for the first time while they are hospitalized with ... death, a new study finds. Atrial fibrillation (AF) ... among critically ill patients, according to background study information. ...
Cached Medicine News:Health News:Better understanding of neurologic defects improves post-cardiac-arrest discharge 2Health News:Exposure to Toxic Solvents Linked to Parkinson's Disease 2Health News:Too Few Doctors Screen Young Athletes for Hidden Heart Trouble 2Health News:Too Few Doctors Screen Young Athletes for Hidden Heart Trouble 3Health News:Girls with family history of breast disease should avoid alcohol 2Health News:Girls with family history of breast disease should avoid alcohol 3Health News:NIH-funded twin study finds occupational chemical exposure may be linked to Parkinson's risk 2Health News:NIH-funded twin study finds occupational chemical exposure may be linked to Parkinson's risk 3Health News:Sepsis Plus Heart Rhythm Disorder Linked to Stroke, Death 2
Woodlyn Lensmeter is designed to be used in either a prescription laboratory setting or professional office. Its titable position angle offers personal comfort. The easily operated marking device pro...
Nidek Fundus Camera NM-200D's compact, lightweight body with user-friendly color touch screen display provides more options to treat more patients, and is more comfortable to use....
... high resolution 1640 x 1280 digital ... - digital achieves new levels of ... use. Now supplied complete with Kowa's ... image and patient management software this ...
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: